Follow
Robert Welte
Robert Welte
GlaxoSmithKline GmbH & Co. KG Germany
Verified email at gsk.com
Title
Cited by
Cited by
Year
A decision chart for assessing and improving the transferability of economic evaluation results between countries
R Welte, T Feenstra, H Jager, R Leidl
Pharmacoeconomics 22 (13), 857-876, 2004
2982004
Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison
S Neubauer, R Welte, A Beiche, HH Koenig, K Buesch, R Leidl
Tobacco control 15 (6), 464-471, 2006
2452006
Direct cost analysis of intensive care unit stay in four European countries: applying a standardized costing methodology
SS Tan, J Bakker, ME Hoogendoorn, A Kapila, J Martin, A Pezzi, G Pittoni, ...
Value in Health 15 (1), 81-86, 2012
1612012
The costs of health damage and productivity losses attributable to cigarette smoking in Germany
R Welte, HH König, R Leidl
The European Journal of Public Health 10 (1), 31-38, 2000
1522000
Health economics of infectious diseases
R Welte, R Leidl, W Greiner, M Postma
Modern Infectious Disease Epidemiology, 249-275, 2009
150*2009
Comparative Model-based Analysis of Screening Programs for Chlamydia trachomatis Infections
M Kretzschmar, R Welte, A Van den Hoek, MJ Postma
American journal of epidemiology 153 (1), 90-101, 2001
1492001
Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach
R WELTE, M KRETZSCHMAR, R LEIDL, A VAN DEN HOEK, JC JAGER, ...
Sexually transmitted diseases, 518-529, 2000
1312000
Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands
JM Bos, H Rümke, R Welte, MJ Postma
Clinical therapeutics 25 (10), 2614-2630, 2003
812003
Costs and effects of chlamydial screening: dynamic versus static modeling
R Welte, M Postma, R Leidl, M Kretzschmar
Sexually transmitted diseases, 474-483, 2005
682005
Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making
R Welte, G Van den Dobbelsteen, JM Bos, H de Melker, L van Alphen, ...
Vaccine 23 (4), 470-479, 2004
502004
Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis infections
B Andersen, J Gundgaard, M Kretzschmar, J Olsen, R Welte, ...
Sexually transmitted diseases, 407-415, 2006
472006
The role of economic evaluation in vaccine decision making
R Welte, CL Trotter, WJ Edmunds, MJ Postma, P Beutels
Pharmacoeconomics 23 (9), 855-874, 2005
382005
Übertragung der Ergebnisse ökonomischer Evaluationsstudien aus dem Ausland auf Deutschland: Probleme und Lösungsansätze.
R Welte, R Leidl
Ansätze und Methoden der ökonomischen Evaluation: eine internationale …, 1999
37*1999
Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program
JM Bos, HC Rümke, R Welte, MJ Postma, JC Jager
Vaccine 20 (1-2), 202-207, 2001
362001
Cost-utility of quadrivalent versus trivalent influenza vaccine in Germany, using an individual-based dynamic transmission model
C Dolk, M Eichner, R Welte, A Anastassopoulou, LA Van Bellinghen, ...
Pharmacoeconomics 34 (12), 1299-1308, 2016
342016
Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review
O Damm, J Witte, S Wetzka, C Prosser, S Braun, R Welte, W Greiner
International Journal of Public Health 61 (7), 847-860, 2016
302016
Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia trachomatis
MJ Postma, R Welte, JAR Van Den Hoek, GJJ Van Doornum, ...
Value in Health 4 (3), 266-275, 2001
282001
Cost impact of prospective HLA-B* 5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
E Wolf, M Blankenburg, JR Bogner, W Becker, D Gorriahn, MC Mueller, ...
European journal of medical research 15 (4), 145-151, 2010
232010
Combination vaccine against invasive meningococcal B and pneumococcal infections
JM Bos, HC Rümke, R Welte, L Spanjaard, L van Alphen, MJ Postma
Pharmacoeconomics 24 (2), 141-153, 2006
232006
Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland
U Siebert, C Behrend, N Mühlberger, J Wasem, W Greiner, ...
Approaches and methods of economic evaluation in health care-an …, 1999
231999
The system can't perform the operation now. Try again later.
Articles 1–20